Biocatalytic access to betazole using a one-pot multienzymatic system in continuous flow by Romero-Fernandez, Maria & Paradisi, Francesca
Green Chemistry
PAPER
Cite this: Green Chem., 2021, 23,
4594
Received 30th March 2021,
Accepted 24th May 2021
DOI: 10.1039/d1gc01095f
rsc.li/greenchem
Biocatalytic access to betazole using a one-pot
multienzymatic system in continuous flow†
Maria Romero-Fernandez a and Francesca Paradisi *a,b
As an alternative to classical synthetic approaches for the production of betazole drug, a one-pot biocata-
lytic system for this pharmaceutical molecule from its alcohol precursor has been developed. An
ω-transaminase, an alcohol dehydrogenase and a water-forming NADH oxidase for in situ cofactor re-
cycling have been combined to catalyse this reaction, yielding 75% molar conversion in batch reactions
with soluble enzymes. This multienzyme system was then co-immobilised through a newly established
protocol for sequential functionalization of a methacrylate-based porous carrier to enable tailored immo-
bilisation chemistries for each enzyme. This pluri-catalytic system has been set up in a continuous flow
packed-bed reactor, generating a space–time yield of up to 2.59 g L−1 h−1 with 15 min residence and a
constant supply of oxygen for in situ cofactor recycling through a segmented air–liquid flow. The addition
of an in-line catch-and-release column afforded >80% product recovery.
Introduction
The use of isolated enzymes as catalysts has been proposed in
the fabrication of important pharmaceutical intermediates. In
fact, the ACS Green Chemistry Institute’s Pharmaceutical
Round Table has published a list of 10 key research areas
aiming to encourage the integration of green chemistry and
engineering into the pharmaceutical industry, and biocatalysis
can provide methodologies for many of these research areas.1
Moreover, the use of one-pot biocatalytic cascade systems in
synthetic applications provides several economic and environ-
mental benefits: fewer unit operations, minimized solvent and
reactor volume, higher throughputs and space–time yields and
reduced waste. In addition, it avoids the separation and purifi-
cation of intermediates and can drive equilibria towards
product formation, consequently enhancing overall yields.2–4
One of the challenges currently faced for the use of biocataly-
sis in synthetic applications stems from enzymes’ limited
stability and water solubility, which hinders their recovery
from the aqueous solution and imposes a major cost-contri-
bution to the process. However, significant mitigation of this
problem can be achieved by enzyme immobilisation, as it can
improve enzyme stability and lead to the development of
heterogeneous biocatalysts, thus increasing enzyme reusability
and simplifying product work-up.5
Betazole is an established drug in the pharmaceutical
industry and a member of the pyrazole derivative family. This
pharmaceutical molecule is an analogue of histamine and a
H2-receptor agonist with the ability of stimulating the
secretion of gastric acid.6,7 Clinical studies confirmed that
betazole stimulation allowed an increase in both serum pepsi-
nogen and gastric acid secretion even in patients with chronic
Chagas’ disease subjected to surgical treatment, where
reduced gastric acid secretion is relevant, since chagasic acha-
lasia surgical treatment alters the esophagogastric junction
anatomy.8
The first synthesis of substituted pyrazoles was carried out
in 1883 by Knorr.9 For betazole, a two step synthesis was pro-
posed by Jones, R.G.7, which evolved from a longer synthetic
route developed in 1949.10 Hydrazine was first reacted with
γ-pyrone in an alcohol solution, affording 3-pyrazoleacetalde-
hyde hydrazone in practically quantitative yields. A Ni-
mediated catalytic hydrogenation of the latter compound
afforded betazole in 80% yield.7 Nowadays, several relevant
synthetic methods are being used to access the substituted
pyrazoles.11
As an alternative to classical synthetic approaches, the
design of a biocatalytic synthetic route for betazole has the
potential to increase the sustainable production of this drug,
but to date it has not been explored. In particular, the biocata-
lytic synthesis of the primary amine of betazole is relevant,
since biocatalysis is a proven powerful tool in the synthesis of
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(enantiopure) amines, which are key intermediates in the
fabrication of numerous active pharmaceutical ingredients
(APIs).1 Both ω-transaminases (TA)12–17 and amine dehydro-
genases (AmDHs)18,19 catalyse the selective production of
primary amines from carbonyl compounds.
Furthermore, the synthesis of amines from the corres-
ponding alcohols offers significant advantages since the
alcohol is mostly easily accessible.20 In fact, different metal-
catalysed methodologies have been proposed to carry out
this reaction.21 No enzyme is however known to directly
aminate an alcohol, and multienzyme systems have been
proposed to catalyse this reaction in a two-step process:
alcohol oxidation to form a carbonyl group, followed by
reductive amination of the latter to produce a primary
amine. Despite the apparent simplicity of the process, the
technical challenges involved in establishing a reliable, sus-
tainable and highly yielding system are significant. To date,
only very few such multienzyme systems have been reported:
galactose oxidase/TA/alanine dehydrogenase (AlaDH);22
alcohol dehydrogenase (ADH)/TA/AlaDH;23,24 ADH/TA/lactate
dehydrogenase;24 ADH/AmDH;25 and alcohol oxidase/TA/
AlaDH/catalase.26
The ADH-catalysed oxidation of alcohols requires stoichio-
metric amounts of oxidised nicotinamide adenine dinucleo-
tide cofactors i.e. NAD(P)+, which represent a major cost con-
tribution to the system. Therefore, an in situ regeneration
system for the oxidised cofactor is essential for ensuring the
cost-efficiency of the process. The integration of water-
forming NAD(P)H oxidase (NOX) enzymes would appear to
be ideal,27 as NAD(P)H is oxidized at the expense of the
most innocuous and cheapest oxidant, O2, and producing
H2O as a by-product.
27 Several water-forming NOX have been
described in the literature.28–30 However, the application of
water-forming NOX to in situ cofactor recycling in continuous
flow methodologies, which are increasing in popularity in
the pharmaceutical industry, is not a straightforward
process. O2 transfer from the gas to the aqueous liquid
phase faces several well-known restrictions.31 Although
efficient O2–liquid transfer can be achieved in conventional
small-scale batch reactors by high levels of aeration and agi-
tation,32 providing O2 to enzymatic reactions is especially
challenging in standard biocatalytic flow reactors operating
only with a liquid phase, where there is little gas (air)–liquid
contact.
The aim of this work is to expand the applicability of syn-
thetic biocatalysis by overcoming existing challenges that limit
its implementation, adopting as a case study the sustainable
production of betazole, a pyrazole derivative of pharmacologi-
cal interest. For this purpose, biocatalysis and flow chemistry
have been integrated to develop a one-pot multienzyme system
in a continuous flow packed-bed reactor (PBR). Moreover, a
novel protocol of multienzyme co-immobilisation on a poly-
methacrylate-based porous bead carrier has been developed.
This system has been successfully applied to catalyse the direct
synthesis of the primary amine of betazole from the corres-
ponding alcohol.
Results and discussion
One-pot multienzymatic cascade combining HLADH, HEWT
and LpNOX
A one-pot enzymatic cascade reaction to catalyse the direct syn-
thesis of the primary amine of betazole from the corres-
ponding alcohol was designed: ADH and TA, together with
water-forming NOX as an in situ cofactor regeneration system.
The use of the S-selective horse liver alcohol dehydrogenase
(HLADH),33,34 the S-selective ω-transaminase from Halomonas
elongata (HeWT),35–37 and the water-forming NADH oxidase
from Lactobacillus pentosus (LpNOX)29,38 was proposed
(Scheme 1).
Initially, the catalytic activity of this multienzyme system on
the alcohol group of 2-(1H-pyrazol-3-yl)ethanol was tested in
batch reactions at a 10 mM scale with a catalytic amount of
NAD+ (0.1 mol equivalents), using isopropylamine (IPA) as the
amino-donor (2 mol equivalents) and the required enzymatic
cofactors. High molar conversion (m.c.), 75%, to betazole was
achieved after 21.5 hours under the specified reaction con-
ditions (Table 1). HLADH and HEWT can therefore catalyse
the functional group interconversion of the alcohol of 2-(1H-
pyrazol-3-yl)ethanol into the corresponding primary amine to
yield betazole in a one-pot system. The presence of LpNOX,
despite its known low stability,29 increases the reaction vel-
ocity, meaning that in situ NAD+ recycling pushes the reaction
equilibrium towards alcohol oxidation (Fig. S1†). This is likely
Scheme 1 One-pot multienzyme system catalysing the functional
group interconversion of the alcohol group of 2-(1H-pyrazol-3-yl)
ethanol to the corresponding primary amine to produce a betazole
drug.
Table 1 Synthesis of the betazole drug in batch reactions catalysed by
soluble HLADH (2 mg mL−1), HEWT (0.2 mg mL−1), and LpNOX (0.1 mg
mL−1). Reaction conditions: 10 mM 2-(1H-pyrazol-3-yl)ethanol in phos-
phate buffer (0.05 M, pH 8), 1 mM NAD+, 20 mM IPA, 0.1 mM flavin
adenine dinucleotide (FAD), and 0.1 mM pyridoxal 5’-phosphate (PLP).
T = 30 °C. Reaction volume = 5 mL
M. c.a (%)
Substrate concentration (mM) 1 h 5 h 21.5 h
10 mM 50 66 75
aDetermined by HPLC.
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due to the high redox potential of the O2/H2O couple that
results in a strong thermodynamic driving force.27
Tailored multienzymatic co-immobilised system
To increase the reusability of this multienzyme system in
continuous flow and simplify product work-up,39 the immo-
bilisation of HLADH, HEWT and LpNOX was achieved.
LpNOX, in particular, proved to be highly challenging.
Among all the immobilisation methods proposed, covalent
immobilisation offers significant advantages as it can
improve enzyme stability by rigidification throughout their
structure,40 and it was successfully attained for HLADH34,41
and HEWT.13 However, despite extensive testing with both
epoxy and glyoxyl chemistries, the obtained recovered activity
of LpNOX was very low even at low catalyst loading (5 mg
g−1) achieving a maximum of 23% with partial immobilis-
ation yield (Table S1†). An alternative immobilisation
method for LpNOX based on ionic adsorption was selected,
and this increased the recovered activity to 33% while pro-
viding the added benefit of enabling the desorption of the
catalyst for replacement with fresh enzyme following exhaus-
tion of the activity.
In addition to the high conversions obtained by multistep
flow biocatalysis in serial reactors for the synthesis of different
molecules,37 one-pot flow biocatalysis based on a multistep
enzymatic synthesis in a single reactor offers significant
advantages.1,4,20 Moreover, immobilising the different
enzymes on the same intrapore bead surface improves further
the performance of biocatalytic cascade systems due to facili-
tated intrapore diffusion of substrates and cofactors between
different enzyme active sites.42–44 Although co-immobilisation
of multienzyme systems is highly challenging since there is no
universal immobilisation chemistry or carrier, selective and
optimal immobilisation of the different enzymes can be
achieved by functionalization of the carrier surface with
different reactive groups.42,44,45 However, no examples have
been reported on polymethacrylate-based carriers, which are
relevant for continuous flow applications.36,46,47 Therefore, a
strategy for the co-immobilisation of this multienzyme system
was developed on a porous bead carrier based on a polymetha-
crylate polymer matrix.
HLADH, HEWT and LpNOX enzymes were co-immobilised
using tailored immobilisation chemistries for each of them.
This was achieved by a novel protocol of sequential
functionalization of a methacrylate carrier with different reac-
tive groups (Scheme 2) to pursue optimal immobilisation for
each of the enzymes and facilitate the diffusion of substrates
between them. The epoxy groups displayed on the carrier
surface were partially hydrolysed to diol groups in a controlled
manner, and diol groups were then oxidised to glyoxyl groups.
The carrier initial epoxy group density was determined to be
94 µmol gcarrier
−1. After partial hydrolysis with H2SO4 and oxi-
dation with NaIO4 treatment, the resulting glyoxyl group
density was 78.3 µmol gcarrier
−1, of which 14% resulted from
the transformation of epoxy into glyoxyl groups, and 86%
resulted from the transformation of diol groups initially
present in the carrier into glyoxyl groups. The initial loading of
epoxy plus diol groups of the carrier was determined to be
161 µmol gcarrier
−1 (Table S2†). Since this strategy also makes
use of the diol groups already present in the carrier, it offers
the advantage of a better usage of the carrier surface and a
higher efficiency of the resulting catalyst.
Scheme 2 Sequential functionalization of the polymethacrylate-based porous bead carrier and co-immobilisation strategy of HLADH, HEWT and
LpNOX. (A) Partial hydrolysis of epoxy groups to diol groups in a controlled manner, and oxidation of diol groups to glyoxyl groups. (B) HLADH
covalent immobilisation on glyoxyl groups at pH 10 and 4 °C for 1 h. (C) Modification of some of the epoxy groups to amine groups upon reaction
with ethylenediamine at pH 8.5. (D) HEWT covalent immobilisation on amino-epoxy groups at pH 8 and 4 °C for 4 h. (E) Blocking of epoxy groups
with polyethyleneimine. (F) Immobilisation of LpNOX by ionic adsorption at pH 7 and 4 °C for 4 h.
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The resulting glyoxyl groups were used to immobilise the
first enzyme, HLADH, by the multipoint-covalent attachment
methodology previously described (Fig. S2†).40,46 This method-
ology is developed under alkaline conditions, where amine
groups from lysine residues of the enzyme react with glyoxyl
groups to form a Schiff’s base which yields a secondary amine
upon reduction with NaBH4.
40 A minor proportion of HLADH
was expected to immobilise via epoxy groups (Fig. S4†). Some
of the remaining epoxy groups (∼12%) were then modified to
amine groups upon reaction with ethylenediamine (EDA). The
second enzyme, HEWT, was covalently immobilised by the
two-step amino-epoxy strategy previously reported.48,49 This
two-step approach is based on the first stabilisation of enzyme
molecules by ionic interaction between their anionic residues
and amine groups of the carrier, prior to the covalent bond
formation between their nucleophilic groups and nearby epoxy
groups on the carrier.48 The aim of this strategy is to overcome
the low reactivity of epoxy groups found in enzyme immobilis-
ation.48 Upon addition of polyethyleneimine (PEI), at least
some of the unreacted epoxy groups covalently reacted with
the amine groups of PEI, which was also used as a scaffold for
the immobilisation by ionic adsorption43,50,51 of the third
enzyme, LpNOX. With this strategy, ionic adsorption of
enzyme molecules is established by ionic interactions between
amine groups of PEI and aspartic and glutamic acid residues
of the enzyme.43
Overall good values of immobilisation yield and recovered
activity were obtained for the three enzymes (Table 2). Note
that the low reported recovered activity for the HLADH could
be possibly attributed to a mass transfer limitation at this high
catalyst loading52 (Fig. S3†). High stability of HLADH and
HEWT was achieved upon covalent immobilisation, and
sufficient stability of LPNOX was reached by ionic adsorption
on PEI (Fig. S5†). As a proof of concept, LpNOX could be
efficiently desorbed by incubation with 0.2 M NaCl and fresh
LpNOX could be immobilised on the same catalyst yielding
35% of the initial specific immobilised activity while preser-
ving HLADH and HEWT immobilised activities (Table S3†)
demonstrating the feasibility of the approach.
The catalytic activity of the resulting co-immobilised multi-
enzyme system was evaluated on the alcohol group of 2-(1H-
pyrazol-3-yl)ethanol in batch reactions under the same con-
ditions as used with soluble enzymes. High m. c., 70%, to the
corresponding primary amine was also achieved after 3 hours
of reaction under specified conditions (Table 3). To
demonstrate the reusability of this co-immobilised
HLADH-HEWT-LpNOX biocatalyst, it was used to catalyse 3
batch reaction cycles. Remarkably, the catalytic efficiency of
this multienzyme system was practically unaltered for 2 batch
reaction cycles of 3 h (Table 3). After the second reaction cycle,
the catalytic efficiency of the co-immobilised multienzyme
system decreased considerably. This is likely due to the low
stability of LpNOX as the activity of immobilised LpNOX on
this multienzyme system dropped to 35% after 2 h of incu-
bation under batch reaction conditions of temperature, pH
and agitation, and to 1.6% after 24 h (Fig. S5†).
Flow biocatalysis with external oxygen supply
A continuous flow PBR was set-up using this co-immobilised
multienzyme system and optimized for the functional group
interconversion of the alcohol of 2-(1H-pyrazol-3-yl)ethanol
into the corresponding primary amine to synthesize the beta-
zole drug. A liquid phase containing 10 mM substrate, catalytic
amounts of NAD+ (0.1 mol equivalents) and IPA (2 mol equiva-
lents), and the required enzymatic cofactors was flowed into
the packed-bed reactor with a residence time of 30 min,
obtaining 10% m. c. (Scheme 3, black).
In systems requiring O2 as a substrate, as is the case for
NOX catalysts, standard flow reactors can be highly limiting
Scheme 3 Continuous biocatalytic production of the betazole drug in
a PBR. Substrate solution: 10 mM 2-(1H-pyrazol-3-yl)ethanol in phos-
phate buffer (0.05 M, pH 8), 1 mM NAD+, 20 mM IPA, 1 mM FAD, 0.1 mM
PLP. T = 30 °C, P = atmospheric pressure. Reactor volume = 3.66 mL. In
red: PBR implementing segmented liquid–gas flow composed of sub-
strate solution/air. In green: PBR implementing recirculation of reaction
solution (9.151 mL reaction solution volume).
Table 3 Synthesis of the betazole drug in batch reaction cycles cata-
lysed by 0.2 g of the (re-used) co-immobilised multienzyme system con-
sisting of HLADH, HEWT and LpNOX per mL of reaction. Reaction con-
ditions: 10 mM 2-(1H-pyrazol-3-yl)ethanol in phosphate buffer (0.05 M,
pH 8), 1 mM NAD+, 20 mM IPA, 0.1 mM FAD, and 0.1 mM PLP. T = 30 °C.
Reaction volume = 1 mL
M. c.a (%)
Batch reaction cycle 2 h 3 h 5 h
1 63 70 71
2 — 64 —
3 — 33 —
aDetermined by HPLC.
Table 2 Immobilisation of 20 mg HLADH, 5 mg HEWT and 5 mg









HLADH 100 9 2.3
HEWT 93 34 6.1
LpNOX 85 33 11.2
a Immobilisation yield (%), recovered activity (%) and specific immobi-
lised activity (U gcarrier
−1) were calculated as described in the
Experimental section.
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unless constant supply of O2 to the liquid phase can be guaran-
teed (e.g. tube-in-tube reactors,53 segmented air–liquid flow reac-
tors32), or a strategy to increase the O2 concentration in the
liquid phase (e.g. pressurized flow reactors31) is implemented. A
simple solution when a packed-bed reactor is employed can be
achieved with a segmented gas–liquid flow strategy composed
of substrate solution/air. To date this was only reported with
whole cell catalysts.32 Here this approach was trialled with cell-
free immobilised catalysts to ensure a constant reservoir of
oxygen to supply the liquid phase for the LpNOX-catalysed
in situ cofactor regeneration in this PBR (Scheme 3, red).
A segmented 50 : 50 substrate solution/air flow was flowed
into the PBR with 15 min residence time. This biphasic flow
allowed alcohol amination with 50% m. c. To our knowledge,
only one example of enzymatic amination of alcohols in con-
tinuous flow has been previously reported.54 However, the
present work is the first example in the literature of a multien-
zyme system applied to amination of alcohols in continuous
flow that uses TA, which is mostly relevant given the broad
range of applications of this type of enzyme in the production
of APIs and their intermediates.17
Recirculation of the reaction mixture through the PBR
increased the m. c. to 72% highlighting a possible limitation
in the residence time. A recirculation strategy of the reaction
mixture (Scheme 3, green) was then further implemented.
A biphasic flow of 50 : 50 substrate solution/air and a resi-
dence time of 4 × 15 min pushed the conversion to 84%. Very
low increment of space time yield (STY) with further passes
was observed after the first pass, where substrate concen-
tration drops to 5 mM. This suggests a km issue and poor enzy-
matic efficiency below such a threshold (≈5 mM) (Fig. S6†).
When the reaction scale was increased to 50 mM, and the
same flow reaction conditions were applied, 23% m. c. to beta-
zole was obtained after 1 pass through this PBR and 66% after
4 passes. STY and catalyst productivity were higher at the
50 mM scale, although conversion was lower (Table 4). At the
30 mM scale, a compromise between conversion and space
time yield was found. At this substrate concentration, 16%
m. c. to betazole was obtained after 1 pass and 69% after 4
passes. After 20 passes, 85% m. c. was achieved.
Assuming a volumetric composition of oxygen in air of
21%, the input oxygen flow rate was 0.025 mL min−1. At 30 °C
and 1 atm, this would be equivalent to 1.012 µmoloxygen min
−1
flowing to the PBR in the gas phase. The molar conversion to
betazole at the 10 mM scale and 15 min residence time after 1
pass was 50%, which corresponded to 0.60 µmol product per
min. At this reaction scale, the input NAD+ concentration was
1 mM; therefore, 0.12 µmolNAD+ min
−1 was flowed into the
system. Since the stoichiometry of the ADH-catalysed alcohol
oxidation and concomitant NAD+ reduction is 1 to 1,
0.48 µmolNAD+ min
−1 must be recycled in 1 pass (at least). This
would indicate that 0.24 µmoloxygen min
−1 were consumed in
the enzymatic reaction under these conditions. In the case of
the 50 mM scale reactions, the oxygen intake rate by the enzy-
matic reaction in the first pass was estimated to be
0.39 µmoloxygen min
−1. Moreover, a segmented liquid–gas flow
was required to ensure a constant reservoir of oxygen to supply
the liquid phase and make the reaction work (only 10%
m. c. was obtained without air supply in the 10 mM reaction).
Therefore, 0.24 µmoloxygen min
−1 were then supplied from the
gas to the liquid phase in the 10 mM scale reaction, and
0.39 µmoloxygen min
−1 in the 50 mM scale reaction, under the
applied flow conditions, and consumed by the enzymatic
reaction.
At the 50 mM scale without any recirculation, this one-pot
multienzymatic system yields 2.59 gbetazole L
−1 h−1 in continu-
ous flow, which is mostly relevant since it represents the first
example of a biocatalytic synthetic step in the fabrication of
betazole. As opposed to classical synthetic routes to this
pharmaceutical molecule,7,11 this metal-free biocatalytic
approach allows the synthesis of the primary amine of betazole
from the corresponding alcohol by means of a highly yielding
system using only water as the solvent at 30 °C and atmos-
pheric pressure, and without the formation of unwanted side-
products. Moreover, the co-immobilisation strategy of this
multienzyme system increased biocatalyst reusability, thus
increasing the catalyst productivity in continuous flow.
Considering a window of 5 h of operational stability of the co-
immobilised multienzyme system under specified flow con-
ditions (Table 4), the accumulated catalyst productivity is
4.8 µmolbetazole mgenzyme
−1.
Finally, a step to trap the primary amine-containing mole-
cules (which include also unreacted IPA as well as betazole)
was integrated in the system. A tailor-made aldehyde resin was
packed in a column and placed downstream of the recirculat-
ing flow reaction. This amine catch-and-release step had an
efficiency of 93% with respect to the recovered betazole after
desorption with 0.2% HCl solution (Fig. S8†). The IPA could
be successfully removed by freeze-drying the eluted fractions,
as shown by 1H NMR and 13C NMR. The betazole-HCl salt
form of the product was isolated with an apparent 94% yield.
The difference with the reaction conversion is due to the pres-
Table 4 Continuous biocatalytic production of the betazole drug
implementing segmented liquid–gas flow composed of substrate solu-
tion/air and recirculation. Recirculated solution volume 9.151 mL.














10 1 × 15 min 50 1.11 0.40
2 × 15 min 72 1.61 0.58
4 × 15 min 84 1.86 0.67
30 1 × 15 min 16 1.07 0.39
2 × 15 min 35 2.28 0.84
4 × 15 min 69 4.53 1.67
20 × 15 min 85 5.60 2.07
50 1 × 15 min 23 2.59 0.96
2 × 15 min 44 4.91 1.81
4 × 15 min 66 7.37 2.72
aDetermined by HPLC. b STY (gbetazole L
−1 h−1) and catalyst pro-
ductivity (µmolbetazole h
−1 mgenzyme
−1) calculated as described in the
ESI.†
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ence of residual phosphate salts from the buffer as confirmed
by 31P NMR.
Conclusions
This work represents the first example of implementation of a
biocatalysed synthetic step in the production of betazole
drugs, and one of the few examples of biocatalytic amination
of alcohols in a continuous flow PBR. It is also the first
cascade which uses TA in continuous flow for the reductive
amination of the formed carbonyl group, which is mostly rele-
vant given the broad range of applications of TA in the pro-
duction of APIs and their intermediates.17 This biocatalytic
strategy could also be integrated with other bio/chemo-cata-
lysed steps to design alternative routes of synthesis of this
drug molecule. The developed segmented gas–liquid flow strat-
egy ensured a constant reservoir of oxygen which further pro-
motes the application of water-forming NOX as recycling
systems in continuous flow PBRs, thus further contributing to
the combination of biocatalysis and flow technologies. The
immobilisation of three different enzymes with tailored chem-
istries shows how optimal conditions can be achieved on the
same carrier even for catalysts with very different stability pro-
files. While the stability of LpNOX was not significantly
improved, the possibility of replenishing the exhausted cata-
lyst, without affecting the other enzymes, was demonstrated.
The method described here has therefore substantial potential
in the synthesis of pure primary amines from the corres-
ponding alcohol intermediates within the production of
numerous APIs, and in the integration of greener synthetic
approaches in the pharmaceutical industry.
Experimental section
Materials
All chemicals and reagents used in this work were purchased
from Sigma-Aldrich unless specified otherwise. GoTaq® DNA
polymerase was purchased from Promega. NheI-HF®,
EcoRV-HF® and T4 DNA ligase were acquired from New
England Biolabs. A QIAquick PCR Purification Kit and a
QIAquick Gel Extraction Kit were purchased from Qiagen.
XL10-Gold® Ultracompetent cells were purchased from
Agilent. E. coli BL21(DE3) Star competent cells were purchased
from Themo Fisher Scientific. Anhydrotetracycline was pur-
chased from Cayman Chemical Company. StrepTrap HP 5 mL
and HisTrap HP 1 mL columns were acquired from GE
Healthcare. Nicotinamide adenine dinucleotide oxidised
(NAD+) and reduced (NADH) forms were purchased from
Apollo Scientific. Relisorb® EP400SS was donated by
Resindion. Polyethyleneimine (PEI) (M.N. 60 000, 50% aq.
solution, branched) was purchased from Acros Organics.
2-(1H-Pyrazol-3-yl)ethanol and betazole were acquired from
Fluorochem.
Cloning of HLADH
The gene coding the horse alcohol dehydrogenase-E-isoen-
zyme (GenBank accession number M64864) was synthesized
by GeneArt Gene Synthesis service from Thermo Fisher
Scientific. The gene was amplified by PCR with GoTaq® DNA
polymerase with the oligonucleotide primers FWD-HLADH (5′-
AATGG ̲C̲T̲A̲G ̲C̲TGGAGCCACCCGCAGTTCGAAAAAGGCGCCATG-
AGCACCGCAG-3′) and RV-HLADH (5′-TAGTTAG ̲A̲T̲A ̲T̲C̲ATTAA-
AAGGTCAGAAT-3′). The primers were designed to incorporate
NheI and EcoRV restriction sites, respectively (underlined).
The manufacturer’s protocol for GoTaq® DNA polymerase PCR
in 50 µL reaction was used. PCR was carried out with 10 µL
5× GoTaq® buffer; 2.5 µL 10 mM FWD-HLADH primer; 2.5 µL
10 mM RV-HLADH primer; 32.5 µL nuclease-free water; 1 µL
100 ng µL−1 plasmid containing the HLADH gene; and 1 µL
GoTaq® DNA polymerase. PCR conditions were 2 min of at
72 °C and 35 cycles of 1 min denaturation at 95 °C, 1 min
annealing at 60 °C and 2 min extension 72 °C. The 35 cycles
were followed by 7 min of final elongation at 72 °C. The ampli-
fied DNA was purified with a QIAquick PCR Purification Kit.
The purified PCR product was digested with NheI-HF® and
EcoRV-HF® for 2 h at 37 °C. The digested gene was gel-
extracted using a QIAquick Gel Extraction Kit and cloned into
the pASK-IBA5plus vector harbouring Lactobacillus brevis ADH,
kindly donated by Prof. Kroutil, digested with the same restric-
tion enzymes. Ligation was developed with T4 DNA ligase fol-
lowing the manufacturer’s guidelines and the resulting
product was used to transform E. coli XL10-Gold®
Ultracompetent cells. The construct was verified by sequencing
and the obtained plasmid was named pASK-IBA5plus-HLADH.
Enzyme expression
The plasmid harbouring HLADH (pASK-IBA5plus-HLADH) was
transformed into E. coli BL21(DE3) Star. 1 L flasks containing
300 mL of Terrific Broth media were inoculated with 10 mL of
an overnight culture in LB and left to grow at 37 °C and 180
rpm until OD600 reached 0.6–0.7. At that point, the expression
was induced with 0.4 µM anhydrotetracycline (final concen-
tration) and the cultures were left to grow for 16 h at 20 °C and
180 rpm. The previously reported expression protocol of
HEWT was followed.35 For LpNOX, a single colony of E. coli
BL21 (DE3) Star cells previously transformed with the plasmid
pET28a-LpNOX, kindly donated by Prof. Sieber,29 was inocu-
lated in autoinduction media ZYP-5052. The cultures were left
to grow at 37 °C and 180 rpm for 20 h. The cells were collected
by centrifugation at 4500 rpm and stored at −20 °C until
further use.
Enzyme purification
The cells containing expressed HLADH enzyme were resus-
pended in 20 mM sodium phosphate buffer, 0.28 M NaCl, and
6 mM KCl pH 7.4. Cells were disrupted by sonication with
pulses of 5 seconds on and 5 seconds off at 60% amplitude for
12 min. The insoluble fraction was separated by centrifugation
at 14 500 rpm for 60 min. The supernatant was filtered
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(0.45 μm) and loaded into a StrepTrap HP 5 mL column using
an ÄKTA™ start FPLC (GE Healthcare). The protein was eluted
with 20 mM sodium phosphate buffer, 0.28 M NaCl, 6 mM KCl
and 2.5 mM D-desthiobiotin pH 7.4. HLADH was dialysed
twice against 50 mM Tris buffer pH 8 at 4 °C. For HEWT, cells
were resuspended in 50 mM potassium phosphate buffer,
0.1 M NaCl, 0.1 mM PLP and 30 mM imidazole pH 8. The same
sonication and centrifugation conditions as in the case of
HADH were used. The supernatant was filtered (0.45 μm) and
HEWT was purified using the ÄKTA™ start FPLC as previously
described.35 HEWT was dialysed twice against 50 mM potass-
ium phosphate buffer 0.1 mM PLP pH 8 at 4 °C. Cells contain-
ing expressed LpNOX enzyme were resuspended in 50 mM pot-
assium phosphate buffer, 0.5 M NaCl, 20 mM imidazole, 10%
(v/v) glycerol, and 0.01 mM flavin adenine dinucleotide (FAD)
pH 8. After cell disruption and insoluble fraction separation
under the same conditions as before, the filtered supernatant
was loaded into a HisTrap HP 1 mL column using the ÄKTA™
start FPLC. The protein was eluted with 50 mM potassium
phosphate buffer, 0.5 M NaCl, 0.5 M imidazole, 10% (v/v)
glycerol, and 0.01 mM FAD pH 8, and dialysed twice against
50 mM Tris buffer 0.01 mM FAD pH 7.5 at 4 °C.
Enzymatic activity assays and determination of protein
concentration
All enzyme assays were performed in triplicate in 96-well
microplates (unless specified otherwise) using an Epoch 2
Microplate Spectrophotometer (Biotek). For HLADH and
HeWT, the activity assays were performed as previously
indicated,34,35 at 25 °C and pH 8 (potassium phosphate
buffer). LpNOX activity assay was performed following the
depletion of NADH at 340 nm using 0.1 mM NADH in 50 mM
phosphate buffer at 25 °C and pH 8. One unit of enzymatic
activity was defined as the oxidation of 1 µmol of cofactor per
minute.
For the immobilised enzyme, the activity was measured
using the same conditions as for the free enzyme. For HLADH
and HEWT, 20 mg of the immobilised biocatalyst were added
to a 10 mL reaction mixture. At regular intervals of time
during 10 min, a sample was taken to measure the absorbance
at 340 nm or 245 nm, for HLADH or HEWT, respectively. For
LpNOX, 20 mg of the immobilised biocatalyst were added to
40 mL of reaction mixture, and the same protocol was fol-
lowed. The specific activity of HLADH, HEWT and LpNOX
immobilised biocatalysts (U gcarrier
−1) was defined as: the for-
mation of NADH in µmol per minute and g of biocatalyst
(HLADH); the formation of acetophenone in µmol per minute
and g of biocatalyst (HEWT); and the depletion of NADH in
µmol per minute and g of biocatalyst (LpNOX).
HLADH and HEWT protein concentration were determined
by UV absorption at 280 nm using an Epoch Take3 Micro-
Volume Plate. The extinction coefficients 22 460 M−1 cm−1 and
62 340 M−1 cm−1, at 280 nm, measured in water, were respect-
ively estimated for HLADH and HEWT using the ExPASy
ProtParam tool, accessible from the ExPASy website (http://
www.expasy.ch). The LpNOX concentration was determined
using a Bradford assay with bovine serum albumin (BSA) as
the standard, as previously reported.29
Sequential functionalization of the methacrylate carrier and
co-immobilisation of HLADH, HEWT and LpNOX
3 g of Relisorb® EP400SS were resuspended in 30 mL of 0.1 M
H2SO4, and the suspension was incubated for 30 min at room
temperature under mild agitation. The hydrolysed carrier was
filtered, washed with H2O and resuspended in 30 mL of
10 mM NaIO4. After 2 h incubation at room temperature under
mild agitation, the resulting carrier was filtered and washed
with H2O (Scheme 2A). The resulting glyoxyl groups were quan-
tified as previously described.46 A 30 mL solution containing
60 mg of pure HLADH in 100 mM NaHCO3 pH 10 was added
to the resin containing glyoxyl groups. The suspension was
incubated for 1 h at 4 °C under mild agitation, and 30 mg of
NaBH4 were then added and further incubated for 30 min at
4 °C under mild agitation. HLADH activity in the remaining
liquid phase before NaBH4 addition was measured. The
immobilised HLADH biocatalyst was filtered and washed with
H2O (Scheme 2B). 2 samples of 20 mg of the immobilised
HLADH biocatalyst were taken to determine the specific
activity of the immobilised HLADH enzyme (in duplicate) as
described before. The rest was added to a 30 mL solution of
300 mM ethylenediamine (EDA) in 100 mM NaHCO3 pH 8.5.
The suspension was incubated for 2 h at room temperature
under mild agitation. The EDA-modified immobilised HLADH
biocatalyst was filtered and washed with H2O (Scheme 2C). A
30 mL solution containing 15 mg of pure HEWT in 50 mM pot-
assium phosphate buffer 0.1 mM pyridoxal 5′-phosphate (PLP)
pH 8 was added to this biocatalyst. After 4 h incubation at 4 °C
under mild agitation, the resulting co-immobilised
HEWT-HLADH biocatalyst was filtered, washed with H2O
(Scheme 2D), and added to a 60 mL solution of 0.05 g PEI per
mL in 25 mM potassium phosphate buffer pH 7.5. The suspen-
sion was incubated for 16 h at room temperature under mild
agitation, and the resulting co-immobilised HEWT-HLADH
biocatalyst was filtered and washed with H2O (Scheme 2E). 4
samples of 20 mg of the co-immobilised HEWT-HLADH bioca-
talyst were taken to determine the specific activity of the
immobilised HEWT and HLADH enzymes (in duplicate). A
30 mL solution containing 15 mg of pure LpNOX in 25 mM
potassium phosphate buffer 0.1 mM FAD pH 7 was added to
this biocatalyst. After 4 h incubation at 4 °C under mild agita-
tion, the resulting co-immobilised LpNOX-HEWT-HLADH bio-
catalyst was filtered and washed with H2O (Scheme 2F).
2 samples of 20 mg of the co-immobilised
LpNOX-HEWT-HLADH biocatalyst were taken to determine the
specific activity of the immobilised LpNOX enzyme (in
duplicate).
The immobilised activity (U gcarrier
−1) was calculated as the
difference between initial offered activity per gram of carrier
and remaining activity in the liquid phase per gram of carrier
at the immobilisation end point. The immobilisation yield (%)
was calculated as the ratio between immobilised activity and
initial offered activity per gram of carrier. The recovered
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activity (%) was calculated as the ratio between the specific
activity of the immobilised enzyme and the immobilised
activity.
Batch reaction of biocatalytic synthesis of the betazole drug
from 2-(1H-pyrazol-3-yl)ethanol
Batch reactions with pure soluble enzymes were performed at
30 °C in 5 mL of reaction mixture containing 10 mM 2-(1H-
pyrazol-3-yl)ethanol, 1 mM NAD+, 200 mM IPA, 0.1 mM PLP,
0.1 mM FAD, 50 mM potassium phosphate buffer pH 8,
HLADH (2 mg mL−1), HEWT (0.2 mg mL−1), and LpNOX
(0.1 mg mL−1). Batch reactions with the co-immobilised multi-
enzyme system were performed at 30 °C in 1 mL of reaction
mixture containing 10 mM 2-(1H-pyrazol-3-yl)ethanol, 1 mM
NAD+, 20 mM IPA, 0.1 mM PLP, 0.1 mM FAD, 50 mM potass-
ium phosphate buffer pH 8, and 0.2 g of the co-immobilised
LpNOX-HEWT-HLADH biocatalyst. The reusability test of the
co-immobilised LpNOX-HEWT-HLADH biocatalyst was devel-
oped in 3 h reaction cycles under the same conditions. After a
reaction cycle, the co-immobilised LpNOX-HEWT-HLADH bio-
catalyst was filtered, washed with H2O and added to a fresh
reaction mixture. The reactions were monitored by HPLC, as
described in the Analytical methods section.
Continuous flow reaction of biocatalytic synthesis of the
betazole drug from 2-(1H-pyrazol-3-yl)ethanol
An Omnifit glass column (6.6 mm i.d. × 100 mm length) was
filled with 3 g of the co-immobilised LpNOX-HEWT-HLADH
biocatalyst to set up a PBR (reactor volume, 3.66 mL). In all the
reactions performed, the temperature was set to 30 °C. A
10 mM substrate solution (2-(1H-pyrazol-3-yl)ethanol) contain-
ing 1 mM NAD+, 20 mM IPA, 0.1 mM PLP, and 1 mM FAD in
50 mM potassium phosphate buffer pH 8.0 was prepared. For
the single-phase flow reaction, this 10 mM substrate solution
was directed into the PBR. The flow rate was kept at 122 µL
min−1 to allow a residence time of 30 min. For two-phase flow
reactions without recirculation, the 10 mM substrate solution
was flowed into the PBR at 122 µL min−1 to allow a residence
time of 15 min with a peristaltic pump. Air was flowed into the
PBR at the same flow rate with a second peristaltic pump and
mixed with the substrate solution stream using a T-junction.
The resulting 50 : 50 substrate solution/air segmented flow was
directed into the PBR. Samples were taken from the exiting
flow streams of single-phase and two-phase flow systems and
analysed by HPLC, as described in the Analytical method
section. For the two-phase flow reactions with recirculation, a
50 mM substrate solution 5 mM NAD+, 100 mM IPA, 0.1 mM
PLP, 1 mM FAD in 50 mM potassium phosphate buffer pH 8.0;
and a 30 mM substrate solution 3 mM NAD+, 60 mM IPA,
0.1 mM PLP, 1 mM FAD in 50 mM potassium phosphate
buffer pH 8.0 were prepared. 9.151 mL of the 10 mM, the
30 mM or the 50 mM substrate solution were flowed at 122 µL
min−1 to allow a residence time of 15 min. The exiting flow
stream was placed in the same container as the substrate solu-
tion. Air was flowed into the PBR at the same flow rate. After
one pass of the 9.151 mL substrate solution (after 75 min), a
sample was taken and analysed by HPLC. The other samples
were taken after 2 and 4 (after 2.5 h and 5 h, respectively).
Amine catch-and-release in continuous flow
3 g of Relisorb® HG400SS were resuspended in 30 mL of
20 mM NaIO4. After 2 h incubation at room temperature under
mild agitation, the resulting carrier was filtered and washed
with H2O. The resulting aldehyde groups were quantified as
previously described.46 An Omnifit glass column (6.6 mm i.d.
× 100 mm length) was filled with 3 g of this tailor-made alde-
hyde resin (column volume, 3.66 mL). The product mixture
resulting from the 30 mM flow reaction (implemented with
segmented flow and recirculation) was flowed to the system.
The flow rate was set up to 122 µL min−1 to allow a residence
time of 30 min (temperature off ). 4 column volumes of 50 mM
phosphate buffer pH 8 were flowed to the system for washing.
The elution of the trapped primary amines by the aldehyde
groups was carried out with 4 column volumes of 0.2% HCl.
Analytical methods
100 μL of sample with a maximum concentration of substrate
(10 mM) were added to 900 μL of MilliQ H2O. The samples
were analysed by HPLC (Accucore™ aQ C18 Polar Endcapped
HPLC Column, Thermo Fisher Scientific (2.6 μm, 4.6 ×
150 mm), measuring at 210 nm, using an isocratic method
with H2O 0.1%TFA) over 5 minutes with a flow rate of 0.8 mL
min−1. The retention times of the different substances were:
2-(1H-pyrazol-3-yl)ethanol 3.45 min, and betazole 2.38 min.
Molar conversions were calculated through a standard curve of
the product.
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